R. Hehlmann

3.1k total citations · 1 hit paper
28 papers, 887 citations indexed

About

R. Hehlmann is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, R. Hehlmann has authored 28 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 13 papers in Genetics and 7 papers in Rheumatology. Recurrent topics in R. Hehlmann's work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (7 papers). R. Hehlmann is often cited by papers focused on Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (7 papers). R. Hehlmann collaborates with scholars based in Germany, United States and Italy. R. Hehlmann's co-authors include Andreas Hochhaus, Susanne Saußele, Michele Baccarani, Valentín García‐Gutiérrez, Delphine Réa, P. Le Coutre, Dragana Milojković, Kimmo Porkka, H. Jean Khoury and Richard E. Clark and has published in prestigious journals such as Blood, Journal of Clinical Microbiology and British Journal of Cancer.

In The Last Decade

R. Hehlmann

26 papers receiving 860 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

2016 330 citations Juan Luis Steegmann, Michele Baccarani et al. Leukemia profile →

Peers

Countries citing papers authored by R. Hehlmann

Since Specialization

Citations

This map shows the geographic impact of R. Hehlmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Hehlmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Hehlmann more than expected).

Fields of papers citing papers by R. Hehlmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Hehlmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Hehlmann. The network helps show where R. Hehlmann may publish in the future.

Co-authorship network of co-authors of R. Hehlmann

This figure shows the co-authorship network connecting the top 25 collaborators of R. Hehlmann. A scholar is included among the top collaborators of R. Hehlmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Hehlmann. R. Hehlmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia breakdown → 2016 ·Leukemia ·Juan Luis Steegmann, Michele Baccarani, Massimo Breccia, Luis Felipe Casado, Valentín García‐Gutiérrez, Andreas Hochhaus, D.-W. Kim, (unknown), H. Jean Khoury, P. Le Coutre, Jiří Mayer, Dragana Milojković, Kimmo Porkka, Delphine Réa, Gianantonio Rosti, Susanne Saußele, R. Hehlmann, Richard E. Clark	330
2	Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms 2014 ·Haematologica ·Tariq I. Mughal, Alessandro M. Vannucchi, Simona Soverini, A. Bazeos, Raoul Tibes, Giuseppe Saglio, Omar Abdel‐Wahab, Animesh Pardanani, R. Hehlmann, Tiziano Barbui, Richard Van Etten, Ayalew Tefferi, J M Goldman	3
3	Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib 2008 ·Haematologica ·Paul La Rosée, (unknown), Helmut König, Nicolai Härtel, Thomas Ernst, J. F. Debatin, Martin Mueller, Philipp Erben, Anja Binckebanck, Lydia Wunderle, Yaping Shou, Margaret Dugan, R. Hehlmann, Oliver G. Ottmann, Andreas Hochhaus	31
4	ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2008 ·Haematologica ·Thomas Ernst, (unknown), Philipp Erben, Benjamin Hanfstein, Armin Leitner, R. Hehlmann, Andreas Hochhaus, M. C. Muller	41
5	Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib 2008 ·Haematologica ·Alice Fabarius, Michael Giehl, (unknown), A. E. J. L. Kramer, Oliver Frank, Claudia Haferlach, Peter Duesberg, R. Hehlmann, Wolfgang Seifarth, Andreas Hochhaus	35
6	Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure 2007 ·Haematologica ·Alice Fabarius, Claudia Haferlach, M. C. Muller, Philipp Erben, Tanja Lahaye, Michael Giehl, Oliver Frank, Wolfgang Seifarth, R. Hehlmann, Andreas Hochhaus	29
7	Abstracts 2006 ·British Journal of Haematology ·Jelena Jovanović, J Score, Katherine Waghorn, Alfred Reiter, (unknown), Giuseppe Saglio, Jane F. Apperley, (unknown), Claude Preudhomme, R. Hehlmann, David Grimwade, Nicholas C.P. Cross	3
8	Das Kompetenznetzwerk „Akute und chronische Leukämien” 2004 ·DMW - Deutsche Medizinische Wochenschrift ·R. Hehlmann, Ute Berger, C. Aul, Th. Büchner, Hartmut Döhner, G. Ehninger, Arnold Ganser, Nicola Gökbuget, (unknown), K. Überla	1
9	Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial 2004 ·British Journal of Cancer ·(unknown), J. T. Hartmann, Andreas Willer, Karin Oechsle, G. Hartung, (unknown), Susanne Saußele, (unknown), Carsten Bokemeyer, R. Hehlmann, Andreas Hochhaus	13
10	Multilobated nuclei in Waldenström’ macroglobulinaemia 2003 ·European Journal Of Haematology ·Georgia Metzgeroth, (unknown), Ole Maywald, (unknown), Ch. Kühn, R. Hehlmann, Jan Hastka	2
11	Systemic Infections with <i>Aspergillus</i> Species in Patients with Hematological Malignancies: Current Serological and Molecular Diagnostic Approaches 2001 ·Oncology Research and Treatment ·Dieter Buchheidt, Birgit Spieß, R. Hehlmann	4
12	Fatal Liver Failure Associated with Valproate Therapy in a Patient with Friedreich's Disease: Review of Valproate Hepatotoxicity in Adults 1999 ·Epilepsia ·S. A. König, Martin Schenk, C. Sick, E. Holm, (unknown), Arthur J. Weiss, Inke R. König, R. Hehlmann	52
13	Analysis of p73 and p53 gene deletions in multiple myeloma 1999 ·Leukemia ·Beate Schultheis, A. Krämer, Andreas Willer, Ute Hegenbart, Hartmut Goldschmidt, R. Hehlmann	24
14	Current Serological and Molecular Methods in the Diagnosis of Systemic Infections with Candida sp. and Aspergillus sp. in Immunocompromised Patients with Hematological Malignancies 1999 ·PubMed ·Dieter Buchheidt, Heyko Skladny, Corinna Baust, R. Hehlmann	2
15	Two Groups of Endogenous MMTV Related Retroviral env Transcripts Expressed in Human Tissues 1997 ·Virus Genes ·Andreas Willer, (unknown), (unknown), (unknown), (unknown), (unknown), R. Hehlmann	13
16	Current Aspects of Drug Therapy in Philadelphia-positive CML: Correlation of Tumor Burden with Survival 1996 ·Leukemia & lymphoma ·R. Hehlmann, H. Heimpel	18
17	Analysis and validation of prognostic factors for CML. German CML Study Group. 1996 ·PubMed ·Joerg Hasford, (unknown), Markus Pfirrmann, R. Hehlmann	23
18	A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia 1996 ·Blood ·Andreas Hochhaus, Andreas Reiter, Heyko Skladny, (unknown), C. Sick, Ute Berger, (unknown), (unknown), R. Hehlmann, JM Goldman, Nicholas C.P. Cross	96
19	Roferon (rIFN-α _2a ) Is More Immunogenic Than Intron A (rIFN-α _2b ) in Patients with Chronic Myelogenous Leukemia 1994 ·Journal of Interferon Research ·Peter von Wussow, R. Hehlmann, (unknown), D Jakschies, (unknown), Otto Prümmer, (unknown), Joerg Hasford, H. Heimpel, H. Deicher	24
20	[AIDS: the beginning of a catastrophe?]. 1987 ·PubMed ·R. Hehlmann	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact